A detailed history of Cowen Prime Advisors LLC transactions in Cassava Sciences Inc stock. As of the latest transaction made, Cowen Prime Advisors LLC holds 1,143 shares of SAVA stock, worth $3,303. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,143
Previous 1,143 -0.0%
Holding current value
$3,303
Previous $27,000 3.7%
% of portfolio
0.01%
Previous 0.01%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 01, 2023

BUY
$27.82 - $44.16 $31,798 - $50,474
1,143 New
1,143 $34,000

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $116M
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Cowen Prime Advisors LLC Portfolio

Follow Cowen Prime Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cowen Prime Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cowen Prime Advisors LLC with notifications on news.